Based on the OSPREY [95] and CONDOR [96] studies, 18F-DCFPyL (Piflufolastat F-18 (PYLARIFY®)) was approved by the FDA in May 2021 for PET detection of PSMA-positive lesions in men with prostate cancer with suspected metastasis [97]. This evidence concerns the gene FOLH1 and prostate carcinoma.